Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Journal of Orthopaedic Research

Volumn 31, Issue 6, 2013, Pages 901-907

  Henrotin, Y ^a   Chevalier, X ^b   Deberg, M ^c   Balblanc, J C ^d   Richette, P ^e   Mulleman, D ^f   Maillet, B ^g   Rannou, F ^h   Piroth, C ⁱ   Mathieu, P ^j   Conrozier, T ^k  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HENRI MONDOR HOSPITAL   (France)

^c Artialis SA   (Belgium)

^d Centre Hospitalier de Belfort Montbeliard   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g Clinique Saint Odilon   (France)

^h Institut Cochin   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

^k HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

biomarker; hyaluronic acid; osteoarthritis; viscosupplementation

Indexed keywords

COLLAGEN TYPE 2; HYALURONIC ACID;

ADULT; ARTICLE; COLLAGEN DEGRADATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLLAGEN TYPE II; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; VISCOSUPPLEMENTS;

EID: 84876281045     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22297     Document Type: Article

References (36)

1. Osteoarthritis G., 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43: 1905-1915 (American College of Rheumatology Subcommittee).
2. Jordan KM, Arden NK, Doherty M, et al. 2003. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62: 1145-1155.
3. Zhang W, Moskowitz RW, Nuki G, et al. 2007. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981-1000.
4. Zhang W, Moskowitz RW, Nuki G, et al. 2008. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137-162.
5. Zhang W, Nuki G, Moskowitz RW, et al. 2010. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18: 476-499.
6. Waddell DD., 2007. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 24: 629-642.
7. Balazs EA., 2004. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 12: 278-289.
8. Bagga H, Burkhardt D, Sambrook P, et al. 2006. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 33: 946-950.
9. Balazs EA., 2003. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 174: 49-62.
10. Gomis A, Miralles A, Schmidt RF, et al. 2007. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain 130: 126-136.
11. Goto M, Hanyu T, Yoshio T, et al. 2001. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19: 377-383.
12. Waddell DD, Kolomytkin OV, Dunn S, et al. 2007. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 465: 241-248.
13. Yatabe T, Mochizuki S, Takizawa M, et al. 2009. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 68: 1051-1058.
14. Biomarkers Definition Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
15. Henrotin Y, Addison S, Kraus V, et al. 2007. Type II collagen markers in osteoarthritis: what do they indicate ? Curr Opin Rheumatol 19: 444-450.
16. 2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13: 258-265.
17. Deberg MA, Labasse AH, Collette J, et al. 2005. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13: 1059-1065.
18. Lejeune JP, Serteyn D, Gangl M, et al. 2007. Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Vet Res Commun 31: 591-601.
19. Gangl M, Serteyn D, Lejeune JP, et al. 2007. A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Res Vet Sci 82: 68-75.
20. Huebner JL, Williams JM, Deberg M, et al. 2010. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 18: 397-405.
21. Ameye LG, Deberg M, Oliveira M, et al. 2007. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 56: 3336-3346.
22. Huebner JL, Kraus VB., 2006. Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. Osteoarthritis Cartilage 14: 923-930.
23. 2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67: 168-174.
24. Conrozier T, Richette P, Balblanc JC, et al. 2010. Les injections intraarticulaires de HYLANE GF-20 réduisent la dégradation du collagène de type II dans la gonarthrose. La Revue du Rhumatisme 77: A46.
25. Conrozier T, Balblanc JC, Richette P, et al. 2012. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: an open-label observational prospective study. J Orthop Res 30: 679-685.
26. Kellgren JH, Lawrence JS., 1957. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16: 494-502.
27. Conrozier T, Mathieu P, Schott AM, et al. 2003. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine 70: 128-133.
28. Karna E, Miltyk W, Surazynski A, et al. 2008. Protective effect of hyaluronic acid on interleukin-1-induced deregulation of beta1-integrin and insulin-like growth factor-I receptor signaling and collagen biosynthesis in cultured human chondrocytes. Mol Cell Biochem 308: 57-64.
29. Surazynski A, Miltyk W, Czarnomysy R, et al. 2009. Hyaluronic acid abrogates nitric oxide-dependent stimulation of collagen degradation in cultured human chondrocytes. Pharmacol Res 60: 46-49.
30. Karna E, Miltyk W, Palka JA, et al. 2006. Hyaluronic acid counteracts interleukin-1-induced inhibition of collagen biosynthesis in cultured human chondrocytes. Pharmacol Res 54: 275-281.
31. Akmal M, Singh A, Anand A, et al. 2005. The effects of hyaluronic acid on articular chondrocytes. J Bone Joint Surg Br 87: 1143-1149.
32. Julovi SM, Ito H, Nishitani K, et al. 2011. Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res 29: 258-264.
33. Peng H, Zhou JL, Liu SQ, et al. 2010. Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. Inflamm Res 59: 519-530.
34. Grishko V, Xu M, Ho R, et al. 2009. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem 284: 9132-9139.
35. Kraus VB, Burnett B, Coindreau J, et al. 2011. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 19: 515-542.
36. Ratner M., 2005. FDA pharmacogenomics guidance sends a clear message to industry. Nat Rev Drug Discov 4: 359.